Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
iECURE (DTIL)/b) reported updated clinical data from the ongoing Phase 1/2 trial of gene-insertion therapy ECUR-506 in neonatal-onset ornithine transcarbamylase (OTC) deficiency, presented at the SSIEM 2026 symposium. According to iECURE, dosing is complete in all three cohorts (low, intermediate, high), with nine participants treated.
As of July 28, 2026, ECUR-506 was generally well tolerated across dose levels, with no unexpected treatment-related safety events, thrombotic microangiopathy, or infusion reactions. In the low-dose cohort, annualized hyperammonemic events were reduced by 57% (p=0.02) and hyperammonemic crises by 74% (p=0.01) versus pre-treatment. Liver biopsies in two low-dose participants and serum PCSK9 reductions supported targeted hepatic editing. One participant achieved a complete clinical response, discontinuing ammonia scavengers and protein restriction, while the other two showed clinical improvements.
Precision BioSciences (Nasdaq: DTIL) has dosed the first patient in August in its Phase 1/2 FUNCTION-DMD clinical trial of PBGENE-DMD, an in vivo ARCUS-based gene-editing therapy for Duchenne muscular dystrophy (DMD). The first dosing occurred at Arkansas Children’s Hospital, a certified Duchenne and MDA care center.
PBGENE-DMD uses two ARCUS nucleases delivered in a single AAV vector to excise exons 45-55 of the dystrophin gene, aiming to enable endogenous production of near full-length functional dystrophin. According to Precision BioSciences, this design could be applicable to up to 60% of DMD patients with mutations in this hotspot region.
The FUNCTION-DMD study is currently enrolling ambulatory boys aged 2–7 years with mutations between exons 45 and 55 at multiple specialized U.S. Duchenne care centers, with initial safety data targeted by year-end 2026.
iECURE (NASDAQ: DTIL), a clinical-stage genome editing company, announced that data from its ongoing OTC-HOPE trial of ECUR-506 in infants with neonatal-onset ornithine transcarbamylase (OTC) deficiency will be featured in an oral presentation at the SSIEM Annual Symposium, held August 25-28, 2026, in Helsinki, Finland.
The talk will present updated safety observations, genome editing data on metabolic control from the low-dose cohort, and analyses of baseline disease severity versus clinical response. The oral presentation, titled “Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration (O-124),” is scheduled for Thursday, August 27, 3:30–5:00 p.m. EEST in Hall 5B, delivered by Julien Baruteau, M.D., Ph.D. iECURE will also exhibit at Booth B16, where its medical team will discuss the OTC-HOPE study and genome editing platform.
Precision BioSciences (Nasdaq: DTIL) reported Q2 2026 results and a business update, highlighting first clinical biopsy evidence from the Phase 1 ELIMINATE-B trial that PBGENE-HBV directly reduces hepatitis B cccDNA. A patient showed a 1-log reduction with <1% cccDNA remaining after two 0.4 mg/kg doses, and repeat dosing in another patient increased anti-cccDNA effect. pgRNA became durably undetectable in 100% of evaluable patients, with substantial S-antigen declines across all dose levels and no dose-limiting toxicities in 16 patients.
PBGENE-DMD advanced with two active Phase 1/2 FUNCTION-DMD trial sites now recruiting, and initial safety data targeted for year-end 2026. Cash, cash equivalents and restricted cash were $112.4 million at June 30, 2026, which Precision expects to fund operations and PBGENE-HBV and PBGENE-DMD data milestones through 2028. Q2 2026 R&D expenses were $12.4 million, G&A $6.8 million, and net loss was $32.7 million, including $13.5 million of other expense driven primarily by non-cash warrant liability revaluation.
Precision BioSciences (Nasdaq: DTIL), a clinical-stage gene editing company, announced it will publish its second quarter 2026 financial results and provide a business update on Thursday, August 6, 2026.
According to Precision BioSciences, its proprietary ARCUS genome editing platform is designed for smaller size, simpler structure, and distinct cutting properties to support sophisticated in vivo gene edits. The pipeline includes clinical-stage candidates such as PBGENE-HBV for viral DNA elimination and PBGENE-DMD for gene excision using dual ARCUS nucleases delivered in a single AAV.
Precision BioSciences (Nasdaq: DTIL) announced senior leadership changes aligned with advancement of its in vivo gene editing programs PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. Effective August 1, 2026, Chief Financial Officer Alex Kelly will become Chief Operating Officer, overseeing key customer-facing functions.
Vice President of Investor Relations and Chief of Staff to the CEO, Naresh Tanna, will be promoted to Chief Financial Officer, leading corporate finance, reporting and investor relations. Chief Development Officer Cindy Atwell continues to oversee clinical development of PBGENE-HBV and PBGENE-DMD and is supported by two newly hired physician leaders in infectious diseases and muscular dystrophy. Chief Scientific Officer Cassie Gorsuch, PhD, now leads all research functions, including clinical-stage translational sciences and next-generation programs, as the company continues to generate clinical data from its ELIMINATE-B and FUNCTION-DMD studies.
Precision BioSciences (Nasdaq: DTIL) reported that on July 5, 2026, its Board Compensation Committee granted inducement equity awards under the company’s 2021 Employment Inducement Incentive Award Plan to three new employees, consistent with Nasdaq Listing Rule 5635(c)(4).
The awards total 114,622 restricted stock units (RSUs), allocated among the three hires as a condition of commencing employment. According to Precision BioSciences, the RSUs vest in substantially equal annual installments over three years, on each of the first three anniversaries of the employees’ respective employment start dates, subject to continued service.
Precision BioSciences (Nasdaq: DTIL) announced its addition to the Russell 2000 Index, effective after the U.S. market close on June 26, 2026. Membership lasts one year and brings automatic inclusion in related growth and value style indexes.
The company is advancing two wholly owned clinical programs and reports a cash runway through 2028.
Precision BioSciences (Nasdaq: DTIL) reported new ELIMINATE-B trial data for PBGENE-HBV in chronic hepatitis B at EASL 2026. Liver biopsies showed a 1-log (10-fold) reduction in cccDNA-derived transcripts after two 0.4 mg/kg doses, with indels inactivating polymerase in the remaining <1% of cccDNA.
PBGENE-HBV achieved durable pgRNA loss in 100% of evaluable patients (n=6) and substantial HBsAg declines in all treated patients (n=15). Across 38 doses in 16 patients, no dose-limiting toxicities occurred; observed Grade 3 lab abnormalities and hypotension were reversible, with mitigation measures reducing severe events.
Precision BioSciences (Nasdaq: DTIL) will host an investor webcast on May 27, 2026, at 8:00 AM EDT. The event will feature Hepatitis B experts and company management discussing new biopsy and clinical data from the ongoing Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B.
The webcast follows late-breaking biopsy data presented at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona. A replay and a separate news release with detailed clinical data will be available on the company’s investor website after the conference embargo lifts.